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Abstract
Background: Drug interactions are an important risk in transplant patients. Case presentation: This case describes an
incident where a patient with islet transplantation, who was using tacrolimus as part of the immunosuppressant regime,
was started on a course of clarithromycin and experienced nephrotoxicity and neurotoxicity. He was an outpatient at that
time and was managed with temporary cessation of tacrolimus until the tacrolimus level returned to target and his
symptoms resolved. He recovered well and was resumed on his usual dosage of tacrolimus to prevent rejection of islets.
Conclusion: Care should be taken with commonly used antibiotics to avoid potentially dangerous interactions with
immunosuppressant drugs.
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Background
Solid organ transplant recipients are at risk for infections.
Prompt antimicrobial therapy may be required. Physicians
should be aware of the potentially dangerous interactions
between some antibiotics and immunosuppressant drugs
commonly used after solid organ transplant.
Tacrolimus is a potent immunosuppressant that is
widely used for prevention of rejection in a variety of
organ transplants. It is metabolized in the liver via cyto-
chrome P450 (CYP) 3A4. Drugs which inhibit CYP3A4
can lead to elevated tacrolimus concentrations resulting in
toxicity. We describe a case of a tacrolimus-clarithromycin
interaction in an islet transplant recipient in order to high-
light the significance of the interaction and to emphasize
that alternatives were available to treat the patient should
a similar situation recur.
Case presentation
A 58 year old male who was diagnosed to have type 1 dia-
betes at age 11 had undergone successful islet transplant-
ation due to life threatening hypoglycemia (pre-transplant
Clarke score [1] = 7/7, HYPO score [2] = 1755 (severe >
1047), post-transplant Clarke score = 0/7, HYPO score =
0) 9 years earlier was maintained on tacrolimus (4.5 mg/
day) and mycophenolate mofetil (2000 mg/day). Target
levels for tacrolimus were 8–10 ng/ml. Prior to the trans-
plant, the patient was on insulin 0.41 unit/Kg/day, and insu-
lin was weaned off after the transplant.
In May 2015, he presented to the emergency department
with a 3 day history of cough and wheeze without fever,
sputum, or hemoptysis. At that time, his HbA1c was 6.1 %,
urine albumin to creatinine ratio 5 mg/mmol, estimated
glomerular filtration rate 70 mL min-1 per 1.73 m2, blood
pressure 125/81 mmHg, body weight 61.1Kg, and body
mass index 23.9 kg/m2.
A chest x-ray showed insignificant non-specific infiltra-
tions. He was discharged with a 10 day supply of oral clari-
thromycin 500 mg twice daily and prednisone 50 mg once a
day for treatment of suspected pneumonia. The patient
asked both the physician and the dispensing pharmacist spe-
cifically whether there might be any interaction with his
transplant medications and was assured there was none.
Five days later, the patient developed severe bilateral hand
tremors and hyperglycemia. Clinical assessment in the trans-
plant program confirmed significant involuntary bilateral
fine hand tremors, marked hyperglycemia (22 mmol/l), but
no fever and normal respiratory examination. Laboratory in-
vestigations confirmed extremely high concentrations of ta-
crolimus (47.2 ng/ml compared with 8.1 ng/ml prior to this
incident) but fortunately only mild nephrotoxicity (serum
creatinine 148 umol/l compared with 111 umol/l before).
Tacrolimus toxicity due to a drug interaction between
tacrolimus and clarithromycin was the most likely cause
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for nephrotoxicity and neurotoxicity. Hyperglycemia was
likely due to a mixture of tacrolimus toxicity and the side
effect of prednisone. Tacrolimus toxicity could result in an
acute decline in renal function which was observed in this
case. Acute rejection could cause hyperglycemia but
would not cause tremors.
Clarithromycin and prednisone were withheld pending
confirmation of tacrolimus toxicity and assessment of
renal function. Hyperglycemia was managed using sub-
cutaneous insulin (0.13 unit/Kg/day) and cessation of
the prednisone. In the absence of any signs or symptoms
of ongoing infection, no antibiotics were given. In retro-
spect, while prednisone might have been warranted as
one of the initial treatments in the emergency depart-
ment due to wheeze, the duration (10 days) and dosage
(50 mg) prescribed were excessive.
Tacrolimus levels and renal function were monitored
twice weekly. By 3 days, the tacrolimus level was
13.3 ng/ml and the tremors had resolved. Tacrolimus
was resumed at his usual dose and maintained in the
target range (8–10 ng/ml).
Insulin therapy was effective to control the hypergly-
cemia and was gradually withdrawn over 2 weeks. Capil-
lary blood glucose monitoring, off insulin, showed fasting
glucose levels consistently around 7 mmol/l, suggesting
adequate islet graft function. His renal function returned
to baseline (creatinine 117 umol/L) at the same time.
Conclusions
CYP 3A4 is the liver enzyme that metabolizes tacroli-
mus, whereas macrolide antibiotics, such as clarithromy-
cin, have been reported to form complexes with CYP
3A4 and inhibit the metabolism of other drugs [3]. The
use of both drugs together will result in increase in cir-
culating tacrolimus concentrations, leading to an in-
creased risk of adverse effects such as nephrotoxicity,
neurotoxicity, and hyperglycemia [4, 5].
There are six cases in the literature involving tacrolimus-
clarithromycin interactions. Wolter et al. reported the first
case in which a renal transplant patient whose tacrolimus
level increased from 9 to 29 ng/ml 3 days after the initiation
of oral clarithromycin 500 mg twice daily for suspected
pneumonia. On the sixth day of clarithromycin treatment,
the tacrolimus concentration peaked at 36 ng/ml with a
concurrent rise in serum creatinine from 327 umol/l to 422
umol/l. Tacrolimus was then withheld and the patient
finished a two-week course of clarithromycin with
normalization of the tacrolimus and creatinine levels [6].
Gomez et al. published two kidney transplant recipients
who, after 9 doses of clarithromycin prescribed for respira-
tory infection, suffered from tacrolimus toxicity resulting in
a concentration peaked at around 30 ng/ml and significant
rise in serum creatinine in both cases. Clarithromycin was
discontinued and tacrolimus was withheld for 1 dose, then
restarted at 75 % of the original dose. The serum creatinine
levels were back to baseline 10 days after the cessation of
clarithromycin [7]. In a retrospective study of the nephrotox-
icity of tacrolimus in 22 renal transplant patients, one patient
was identified to have suffered from a rise in both the drug
level and serum creatinine attributed to concomitant use of
clarithromycin [8].
This adverse drug interaction is not limited to kidney
transplant patients. Ibrahim et al. described this interaction
in a bone marrow transplant recipient. The patient was on
tacrolimus for the prevention of graft-versus-host disease
after receiving an unrelated donor hematopoietic stem-cell
transplant. He was treated with oral clarithromycin 500 mg
twice daily as part of the antibiotic regime in an episode of
acute lobar pneumonia 4 months after the procedure. To-
tally, 8 doses of clarithromycin 500 mg were given with ta-
crolimus 4 mg, resulting in an elevation of tacrolimus from
6.3 ng/ml to 10.1 ng/ml, and serum creatinine from 97
umol/l to 150 umol/l. Clarithromycin was stopped and ta-
crolimus was withheld. After 2 days of discontinuation of
clarithromycin, tacrolimus was resumed at 3 mg twice daily.
Unfortunately, the patient developed severe pneumonia and
died shortly afterwards [9]. Similarly, such interaction was
documented in a pharmacokinetic study on a heart trans-
plant recipient who was on long-term tacrolimus for im-
munosuppression who required a seven-day course of
clarithromycin as part of the triple therapy against Helico-
bacter pylori identified in gastroscopy. Tacrolimus was re-
duced from 6 to 4 mg per day pre-emptively before
clarithromycin use and 3 doses of tacrolimus was withheld
at the completion of the clarithromycin course, with phar-
macokinetic parameters recorded along the line. The tacroli-
mus dose were then gradually increased over the next
4 days up to 3 mg per day on the seventh day from discon-
tinuation of clarithromycin. The pharmacokinetic profile re-
vealed elevation of tacrolimus concentrations when
clarithromycin was in use. The serum creatinine levels for
this patient were relatively stable, and this might be due to a
different types of transplanted organ and/or individual kid-
ney function, as compared to the other 5 reported cases and
our case in which serum creatinine levels were raised when
the tacrolimus levels were high [10]. Though all of the previ-
ously reported cases focused on nephrotoxicity, neurotox-
icity is another well documented adverse effect from
tacrolimus overdose. Mechanisms underlying tacrolimus
neurotoxicity include damage of the astrocytes at the
blood–brain barrier, excess production of endothelin result-
ing in vasospasm causing local ischemia and edema at cere-
brum, and alterations in mitochondrial function leading to
apoptotic cell death [11].
In our experience, azithromycin, another macrolide
antibiotic, is an alternative to clarithromycin because this
antibiotic has a very similar microbiological spectrum
while it does not interact significantly with CYP 3A4
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enzyme. It should also be noted that other drugs which
are metabolized via the same enzyme system should also
be used with caution for patients on tacrolimus, such as:
ketoconazole, itraconazole, troleandomycin, nelfinavir, ri-
tonavir, and nefazodone [12].
To our knowledge, this case is the first case report of a
tacrolimus-clarithromycin interaction in an islet trans-
plant recipient. Clinicians need to be reminded of this
significant drug interaction, which might occur within
3–5 days of concomitant administration, and consider
other alternative antibiotics in treatment of infections.
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